Compare · CEMI vs NEOG
CEMI vs NEOG
Side-by-side comparison of Chembio Diagnostics Inc. (CEMI) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CEMI and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG carries a market cap of $2.37B.
- NEOG has hit the wire 13 times in the past 4 weeks while CEMI has been quiet.
- NEOG has more recent analyst coverage (6 ratings vs 1 for CEMI).
- Company
- Chembio Diagnostics Inc.
- Neogen Corporation
- Price
- -
- -
- Market cap
- -
- $2.37B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 0
- 13
- Recent ratings
- 1
- 6
Chembio Diagnostics Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest CEMI
- SEC Form 15-12G filed by Chembio Diagnostics Inc.
- SEC Form SC 13D/A filed by Chembio Diagnostics Inc. (Amendment)
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form 4 filed by Angelico Paul
- SEC Form 4 filed by Acheson David
- SEC Form 4 filed by Eberly Richard
Latest NEOG
- Chief Scientific Officer Yarwood Jeremy exercised 16,207 shares at a strike of $11.82, covered exercise/tax liability with 7,156 shares and sold $114,676 worth of shares (9,051 units at $12.67) (SEC Form 4)
- Neogen Corporation filed SEC Form 8-K: Other Events
- Chief Commercial Officer Freels Joe B was granted 6,345 shares (SEC Form 4)
- Neogen® To Participate in 2026 UBS Global Healthcare Conference
- VP, Animal Health Hastings Gregory S exercised 1,211 shares at a strike of $12.21 and covered exercise/tax liability with 337 shares, increasing direct ownership by 3% to 33,449 units (SEC Form 4)
- Director Woteki Catherine E exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 6% to 29,507 units (SEC Form 4)
- Director Rodriguez Rafael A exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 6% to 31,211 units (SEC Form 4)
- SEC Form 3 filed by Neogen Corporation
- Director Gupta Aashima exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 5% to 38,180 units (SEC Form 4)
- Director Green Ronald D exercised 1,776 shares at a strike of $12.21, increasing direct ownership by 7% to 29,044 units (SEC Form 4)